Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients

Neuropsychopharmacology

Volumn 31, Issue 4, 2006, Pages 825-831

  Suzuki, Yutaro ^a   Sawamura, Kazushi ^a   Someya, Toshiyuki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

5 HT2A; CytochromeP4502D6; Fluvoxamine; Genetic polymorphism; Side effects

Indexed keywords

CISAPRIDE; CYTOCHROME P450 2D6; FLUVOXAMINE; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR;

ADULT; ALLELE; ANOREXIA; ANXIETY; ARTICLE; ASIAN; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG METABOLISM; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEADACHE; HUMAN; INCIDENCE; INFORMED CONSENT; INSOMNIA; IRRITABILITY; JAPAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SIDE EFFECT; SOMNOLENCE; STOMACH PAIN; SYMPTOM; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHI-SQUARE DISTRIBUTION; CYTOCHROME P-450 CYP2D6; DEPRESSION; FEMALE; FLUVOXAMINE; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROLINE; RECEPTOR, SEROTONIN, 5-HT2A; SERINE; TYROSINE;

EID: 33645024572     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300919     Document Type: Article

References (24)

1. Banes A, Florian JA, Watts SW (1999). Mechanisms of 5- hydroxytryptamine(2A) receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther 291: 1179-1187.
2. Bergeron R, Blier P (1994). Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry 151: 1084-1086.
3. Bertilsson L, Dahl ML (1996). Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 5: 200-223.
4. Bourin M, Chue P, Guillon Y (2001). Paroxetine: a review. CNS Drug Rev 7: 25-47.
5. Bray NJ, Buckland PR, Hall H, Owen MJ, O'Donovan MC (2004). The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain. Mol Psychiatry 9: 109-114.
6. Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Korner J et al (1996). Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 97: 614-619.
7. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H et al (2003). Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology (Berl) 167: 443-448.
8. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI (1998). Drug interactions with newer antidepressants: role of human cytochromesP450. J Clin Psychiatry 59(Suppl 15): 19-27.
9. Hartter S, Wetzel H, Hammes E, Torkzadeh M, Hiemke C (1998). Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial. Pharmacopsychiatry 31: 199-200. http://www.imm.ki.se/CYPalleles/.
10. Janssen P, Prins NH, Meulemans AL, Lefebvre RA (2002). Pharmacological characterization of the 5-HT receptors mediating contraction and relaxation of canine isolated proximal stomach smooth muscle. Br J Pharmacol 136: 321-329.
11. Johansson I, Oscarson M, Yue Q, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M (1994). Genetic analysis of the Chinese cytochrome P4502D6 locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for deberisoquine hydroxylation. Mol Pharmacol 46: 452-459.
12. Kaiser R, Tremblay PB, Sezer O, Possinger K, Roots I, Brockmoller J (2004). Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics 14: 271-278.
13. Kasper S, Fuger J, Moller HJ (1992). Comparative efficacy of antidepressants. Drugs 43(Suppl 2): 11-22; discussion 22-23.
14. Landolt HP, Meier V, Burgess HJ, Finelli LA, Cattelin F, Achermann P et al (1999). Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 21: 455-466.
15. Murphy Jr GM, Kremer C, Rodrigues HE, Schatzberg AF (2003). Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160: 1830-1835.
16. Niesler B, Flohr T, Nothen MM, Fischer C, Rietschel M, Franzek E et al (2001). Association between the 5′ UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics 11: 471-475.
17. Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, Makoff AJ (2004). The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 56: 406-410.
18. Polesskaya OO, Sokolov BP (2002). Differential expression of the 'C' and 'T' alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 67: 812-822.
19. Sargent PA, Williamson DJ, Cowen PJ (1998). Brain 5-HT neurotransmission during paroxetine treatment. Br J Psychiatry 172: 49-52.
20. Someya T, Shimoda K, Suzuki Y, Sato S, Kawashima Y, Hirokane G et al (2003). Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. Neuropsychopharmacology 28: 1501-1505.
21. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen A-L, Idle JR et al (1995). Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5: 215-223.
22. Tremblay PB, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K et al (2003). Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 21: 2147-2155.
23. Trindade E, Menon D, Topfer LA, Coloma C (1998). Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 159: 1245-1252.
24. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M et al (2003). Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology 48: 10-13.